MCRB — Seres Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $124.58m
- $98.16m
- $126.33m
- 20
- 37
- 19
- 15
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 34.5 | 33.2 | 145 | 7.13 | 126 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 106 | 121 | 209 | 254 | 236 |
Operating Profit | -71.9 | -88.1 | -64.5 | -246 | -110 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -70.3 | -89.1 | -65.6 | -250 | -114 |
Net Income After Taxes | -70.3 | -89.1 | -65.6 | -250 | -114 |
Net Income Before Extraordinary Items | |||||
Net Income | -70.3 | -89.1 | -65.6 | -250 | -114 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -70.3 | -89.1 | -65.6 | -250 | -114 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.21 | -1.12 | -0.715 | -2.31 | -0.876 |